Shuttle Pharmaceuticals Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $4.1M | $3.6M | $3.5M | $1.0M | $1.0M |
| Operating expenses | $11.9M | $7.7M | $5.9M | $2.3M | $1.7M |
| Operating income | -$11.9M | -$7.7M | -$5.9M | -$2.3M | -$1.7M |
| Pretax income | — | — | -$6.6M | -$5.0M | -$1.2M |
| Net income | -$11.7M | -$9.1M | -$6.6M | -$5.0M | -$1.2M |
| Balance Sheet | |||||
| Cash and equivalents | $334,005 | $1.9M | $2.6M | $8.4M | $504,749 |
| Current assets | $502,911 | $2.2M | $5.6M | $8.6M | $509,615 |
| Total assets | $10.5M | $2.5M | $6.0M | $8.7M | $651,641 |
| Current liabilities | $8.0M | $1.5M | $1.0M | $975,676 | $2.2M |
| Total liabilities | $8.2M | $1.8M | $1.9M | $975,676 | $2.3M |
| Total debt | — | — | — | — | $500,000 |
| Stockholders' equity | $2.3M | $709,152 | $4.1M | $7.7M | -$1.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$9.5M | -$7.3M | -$5.6M | -$2.7M | -$300,336 |
| Depreciation and amortization | $290,107 | $5,463 | $6,811 | $5,972 | $6,218 |
| Stock-based compensation | $932,967 | $259,744 | $181,960 | $237,547 | $910,067 |
| Capital expenditure | — | — | $19,046 | — | — |
| Free cash flow | — | — | -$5.6M | — | — |
| Impairments | $109,235 | — | — | — | — |
Shares outstanding 5.9M · Free float 26.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.